Health News

Data related to ZYTIGA (abiraterone acetate) will be presented at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Read more

Filed under: Pharmacy News
Tags: cancer, Oncology, Pharmacy, Prostate Cancer

Related posts

• ZIOPHARM announces darinaparsin preclinical data on prostate cancer (0)
  ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, announced today that results from preclinical studies of darinaparsin (Zinapar or ZIO-101), a novel organic arsenic, in prostate cancer were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place November 12-16 in San [...]
  
  
• Study Of Investigational Agent Abiraterone Acetate For Metastatic Advanced Prostate Cancer Unblinded After Meeting Pre-Determined Criteria (0)
  Ortho Biotech Oncology Research & Development, a unit of Cougar Biotechnology, Inc... Read more [tags] Pharmacy News [/tags]
  
  
• Scientists study a botanical formula that kills aggressive prostate cancer tumors (0)
  Scientists at Indiana University, Methodist Research Institute study a botanical formula that kills aggressive prostate cancer tumors. Their findings, based on experiments in mice using a human prostate cancer tumor model, appear online in The International Journal of Oncology. Read more [tags] Pharmacy News [/tags]
  
  
• Poniard Pharmaceuticals’ picoplatin Phase 2 study in metastatic CRPC: Positive results (0)
  Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, today announced the presentation of positive final data, including survival data, from the Company's Phase 2 clinical trial of picoplatin as a first-line therapy in men with metastatic castration-resistant (hormone-refractory) prostate cancer (CRPC). The results were presented in a General Poster Session today [...]
  
  
• Poniard Pharmaceuticals Presents Positive Survival Data From A Phase 2 Clinical Study Of Picoplatin In Metastatic Prostate Cancer (0)
  Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, announced the presentation of positive final data, including survival data, from the Company's Phase 2 clinical trial of picoplatin as a first-line therapy in men with metastatic castration-resistant (hormone-refractory) prostate cancer (CRPC)... Read more [tags] Pharmacy News [/tags]